Q Therapeutics Inc., of Salt Lake City, received U.S. Patent No. 7,214,372, titled "Methods Using Lineage Restricted Glial Precursors from the Central Nervous System." It contains claims to methods for increasing remyelination of neurons in patients suffering from diseases or conditions associated with demyelination of neurons.

Rosetta Genomics Ltd., of Rehovot, Israel, received a notice of allowance for two patent applications on human and viral microRNAs. The first claims focus on a human microRNA gene (mir-492), and the second claims focus on an HIV microRNA gene.

Targeted Genetics Corp., of Seattle, received U.S. Patent No. 7,186,552, titled "Adeno-Associated Virus (AAV) Serotype I Nucleic Acid Sequences, Vectors and Host Cells Containing Same." It describes the use of AAV Vectors containing inverted terminal repeat and capsid sequences derived from AAV serotype I and host cells transduced with such vectors.

ValiRx plc, of London, received a patent relating to its gene-silencing technology, GeneICE, which is held by subsidiary Cronos Therapeutics Ltd. GeneICE compounds have the potential to freeze the development and growth of cancerous cells and also have potential in inflammatory disease and genetic conditions.